Related Experiment Video

Updated: Jun 13, 2025

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

2.7K

Perindopril decreases angiotensin-converting enzyme 2 (ACE2) expression in human adipocytes exposed to SARS-CoV-2 S1

Primasitha M Harsoyo1,2, Meity Ardiana1,2, Hanestya O Hermawan1,2

  • 1Department of Cardiology and Vascular Medicine, Faculty of Medical, Universitas Airlangga, Surabaya, Indonesia.

Narra J
|September 16, 2024
PubMed

Insights

Perindopril, an angiotensin-converting enzyme 2 (ACE2) inhibitor, significantly reduced ACE2 expression and IL-6 levels in adipocytes exposed to SARS-CoV-2 spike protein. This suggests a potential therapeutic role in managing viral infections.

Area of Science:

  • Endocrinology
  • Virology
  • Pharmacology

Background:

  • Obesity is linked to increased angiotensin-converting enzyme 2 (ACE2) expression in adipose tissue, potentially facilitating viral infections like COVID-19.
  • The role of ACE inhibitors, such as perindopril, in modulating ACE2 expression and its impact on viral pathogenesis remains unclear.

Purpose of the Study:

  • To investigate the effect of perindopril on ACE2 expression and pro-inflammatory cytokine levels in adipocytes exposed to SARS-CoV-2 S1 spike protein.

Main Methods:

  • Adipose tissues from obese male donors were enzymatically isolated and exposed to SARS-CoV-2 S1 spike protein.
  • ACE2 expression was quantified using ELISA, with human recombinant ACE2 (hrsACE2) and perindopril as treatments.
  • Interleukin-6 (IL-6) levels were also assessed.

Main Results:

  • Exposure to SARS-CoV-2 Spike protein significantly increased ACE2 expression in adipocytes.
  • Perindopril administration markedly decreased ACE2 expression (43.37 μg/mL) compared to the positive control (80.31 μg/mL) (p<0.001).
  • Perindopril treatment also significantly reduced IL-6 levels (p<0.001).

Conclusions:

  • Perindopril effectively reduces ACE2 expression in adipocytes stimulated by SARS-CoV-2 S1 spike protein.
  • Perindopril demonstrates anti-inflammatory effects by decreasing IL-6 levels in this context.
  • These findings suggest perindopril's potential therapeutic benefit in mitigating viral infections associated with elevated ACE2 expression.
Keywords:
ACE2IL-6SARS-CoV-2obesityperindopril

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.8K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510
Adrenergic Receptors: &#946; Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K
Adrenergic Receptors: &#593; Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398